Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina
Top Cited Papers
- 1 April 2004
- journal article
- clinical trial
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 43 (8) , 1375-1382
- https://doi.org/10.1016/j.jacc.2003.11.045
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Metabolic Approaches to the Treatment of Ischemic Heart Disease: The Clinicians' PerspectiveHeart Failure Reviews, 2002
- Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the ratEuropean Journal of Pharmacology, 2001
- Protective Effects of Ranolazine, a Novel Anti-ischemic Drug, on the Hydrogen Peroxide-Induced Derangements in Isolated, Perfused Rat Heart: Comparison With DichloroacetateThe Japanese Journal of Pharmacology, 1998
- Protective Effects of Ranolazine on Ventricular Fibrillation Induced by Activation of the ATP-Dependent Potassium Channel in the Rabbit HeartJournal of Cardiovascular Pharmacology and Therapeutics, 1996
- Ranolazine Increases Active Pyruvate Dehydrogenase in Perfused Normoxic Rat Hearts: Evidence for an Indirect MechanismJournal of Molecular and Cellular Cardiology, 1996
- Ranolazine Stimulates Glucose Oxidation in Normoxic, Ischemic, and Reperfused Ischemic Rat HeartsCirculation, 1996
- Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heartCardiovascular Research, 1994
- Protective effects of ranolazine in guinea‐pig hearts during low‐flow ischaemia and their association with increases in active pyruvate dehydrogenaseBritish Journal of Pharmacology, 1993
- Prevention of myocardial enzyme release by ranolazine in a primate model of ischaemia with reperfusionBritish Journal of Pharmacology, 1990
- The effects of the novel anti-anginal agent RS 43285 on [lactic acid], [K+] and pH in a canine model of transient myocardial ischaemiaBiochemical Society Transactions, 1987